Azilsartan  tablets

Azilsartan tablets

Form: Tablets

Strength: 40 mg

Reference Brands: Edarbi(EU), Takarta(US)

Category: Hypertension

Azilsartan tablets, marketed as Edarbi in the EU and Takarta in the US, are approved for hypertension management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Supporting regional compliance facilitates timely approval, safe use, and global availability of azilsartan tablets, helping patients worldwide control blood pressure and reduce cardiovascular risks effectively.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Antithymocyte Globulin (ATG) powder for injection

Strength: 250mg/5ml

Form: Lyophilized powder

Reference Brands: Thymoglobulin(US & EU)

View Details Get Enquiry
Hydralazine tablets

Strength: 10 mg, 25 mg, 50 mg, 100 mg

Form: Tablets

Reference Brands: Apresoline(US & Eu)

View Details Get Enquiry
Methyldopa tablets

Strength: 250 mg, 500 mg, and 750 mg

Form: Tablets

Reference Brands: Aldomet(US)

View Details Get Enquiry
Clonidine Patch

Strength: 0.1 mg/24 hours, 0.2 mg/24 hours, 0.3 mg/24 hours

Form: transdermal patch

Reference Brands: Catapres(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.